Elizabeth Balta - 15 Feb 2023 Form 4 Insider Report for Icosavax, Inc.

Reporting relationship: General Counsel & Corp. Sec.
Issuer ticker: N/A
Reported as of: 15 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Feb 2023, 18:13:07 UTC
Prior SEC filing: 15 Feb 2023
Next SEC filing: 01 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Bekiroglu

Key filing fact

Elizabeth Balta filed Form 4 for Icosavax, Inc. on 17 Feb 2023.

Key facts

This page summarizes Elizabeth Balta's Form 4 filing for Icosavax, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Feb 2023, 18:13.

Change

Previous filing in this sequence was filed on 15 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ICVX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 15 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $9.06
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option will vest on February 15, 2024, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the reporting person's continued service through the applicable vesting date.